NBIX Stock Price Today (October 2026) — Neurocrine Biosciences, Inc. Analysis & Key Metrics 2026-10-07
Neurocrine Biosciences, Inc. (NBIX) is trading at $143.47, down 1.40% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $207.81 (44.8% upside).
- Volatility is low (22.48% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (39.50% YoY) alongside competitive pressures in the Drug Manufacturers - Specialty & Generic space.
NBIX Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Neurocrine Biosciences, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $14.66B
P/E Ratio
Forward P/E: 12.89
Revenue Growth
Year over Year
Analyst Target
+44.8% upside potential
Key Investor Questions About NBIX
What investors need to know before buying
Based on current market data, NBIX presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 45.03)
- Fundamentals say: Looking solid (debt and growth supportive)
NBIX's growth trajectory depends on its ability to expand within the Drug Manufacturers - Specialty & Generic sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - Specialty & Generic operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for NBIX investors include debt exposure and competitive dynamics in the Drug Manufacturers - Specialty & Generic industry.
- $461.60M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - Specialty & Generic.
52-Week Trading Range
Over the past year, NBIX stock traded between $122.14 and $186.12 and currently trades in the middle of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 22.48% annualized volatility and β=0.64, the stock exhibits low sensitivity to market moves—making NBIX suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Lower institutional support combined with high short selling points to negative sentiment.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit
Neurocrine Biosciences (NASDAQ:NBIX) outlined its commercial growth priorities, pricing considerations and pipeline plans during a Morgan Stanley discussion, with CEO Kyle Gano emphasizing the company’s efforts to diversify beyond its largest product, INGREZZA. Gano said China has become both a com
Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story
On August 12, Neurocrine Biosciences (NASDAQ:NBIX) published something unusual for a psychiatric drug: proof that patients feel the difference, not just that a clinician’s scale says they moved less. The KINECT-PRO findings showed INGREZZA easing the daily burden of tardive dyskinesia in ways a rating scale alone never captures. The timing matters, because the data […]
Neurocrine Biosciences' Ingrezza, Crenessity to Drive H2 Ahead of 'Catalyst-Rich' 2027, RBC Says
Neurocrine Biosciences' (NBIX) Ingrezza and Crenessity products are expected to drive H2 appreciatio
Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?
NBIX's Crenessity gains rapid traction in CAH, with sales soaring and low patient penetration leaving room for growth.
Neurocrine Biosciences (NBIX) Wins FDA Trial Nod, Is It Still Below Fair Value?
Neurocrine Biosciences (NBIX) drew investor attention after the FDA accepted its Investigational New Drug application for a Phase 2 trial of NBI-1117567 in Alzheimer’s cognition, marking a fresh clinical milestone in its Nxera partnership. Despite the FDA news, Neurocrine Biosciences’ recent 30 day share price return is down 14.72%. However, the year to date share price return of 10.90% and 1 year total shareholder return of 12.22% point to momentum that has built over a longer horizon. Scan...
Did Nxera’s Alzheimer’s Milestone and IND Progress Just Shift Neurocrine Biosciences' (NBIX) Investment Narrative?
Nxera Pharma recently announced that its partner Neurocrine Biosciences received FDA IND acceptance for a Phase 2 trial of NBI-1117567, an investigational oral muscarinic M1-preferring agonist for Alzheimer’s cognition, triggering a US$10,000,000 milestone payment to Nxera in Third Quarter Fiscal Year 2026. This IND milestone advances Neurocrine’s broader muscarinic receptor collaboration with Nxera, underscoring its push into Alzheimer’s-related cognitive symptoms alongside existing...
Neurocrine Biosciences (NBIX) Stock Looks Fairly Priced As 64% Gain Holds
Neurocrine Biosciences stock has delivered a solid 5 year return while recent trading has been more mixed, and the current share price around US$156 still raises the question of how much value is already reflected. With the broader valuation checks leaning supportive and the market multiples screening as roughly in line with peers, investors are weighing whether the stock still offers an attractive entry point. Over the past 5 years Neurocrine Biosciences has returned 63.8%, which puts the...
Neurocrine Biosciences (NBIX) Cleared For Phase 2 Alzheimer’s Cognition Study
Neurocrine Biosciences (NasdaqGS: NBIX) reported that the FDA has accepted its Investigational New Drug application for NBI-1117567 targeting Alzheimer's related cognition. The acceptance clears the way for a Phase 2 clinical study of NBI-1117567 in patients with cognitive symptoms linked to Alzheimer's disease. This IND milestone adds another clinical stage asset to Neurocrine Biosciences' development pipeline in a high unmet need area. This kind of progress in Alzheimer's drug development...
NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.
Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?
Neurocrine's Q2 beat and higher Ingrezza guidance highlight strong growth, but rising spending and execution risks could test its expanding portfolio.
Explore More Analysis for NBIX
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 3, 2026 (after the close, usually)
Frequently Asked Questions
Common investor questions about Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. (NBIX) is currently trading at $143.47. The RSI (14-day) is at 45.0, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $207.81 implies 44.8% upside from current levels. Volatility is moderate at 22.5% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Neurocrine Biosciences, Inc. (NBIX): The trailing P/E ratio is 22.99, which is in line with broader market averages. The forward P/E is 12.89, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.46, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 4.32. Price-to-Sales is 4.74. Valuation should be compared to Drug Manufacturers - Specialty & Generic industry peers for context, as different sectors trade at different multiples.
Based on 29 analysts covering NBIX, the consensus price target is $207.81. This represents a 44.8% upside from the current price of $143.47. The range spans from a low target of $164.00 to a high target of $253.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Neurocrine Biosciences, Inc. (NBIX) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Neurocrine Biosciences, Inc. (NBIX) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Drug Manufacturers - Specialty & Generic sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Neurocrine Biosciences, Inc.'s (NBIX) current debt and financial health profile: Total debt stands at $461.60M. The debt-to-equity ratio is 0.12x, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 1.87, indicating strong short-term liquidity. The quick ratio is 1.46. The company holds $389.80M in cash and equivalents. Free cash flow is positive at $638.24M, providing a cushion for debt servicing and shareholder returns.